Magle Chemoswed Holding AB (publ), reg. no. 556913-4710 ("Magle Group" or the "Company"), announces that the Company has today, 4 November 2026, given notice of termination of its agreement with Pareto Securities AB as liquidity provider for the Company’s shares. Pareto Securities AB will cease to act as liquidity provider for the Company’s shares with effect from today.

The decision is based on the upcoming delisting of the Company’s shares from Nasdaq First North Growth Market.

Contacts

Aaron Wong, CEO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. Today, the Group includes two operational areas. Magle Chemoswed – a contract manufacturing organization (CMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle Biopolymers A/S - a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglebiopolymers.com

Redeye Nordic Growth AB is the company's Certified Adviser.

Attachments

Magle Chemoswed Holding AB (publ) terminates liquidity provider agreement regarding trading in the company’s shares